Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | TTR | P02766 | 1/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.54 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.54 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5266458 | 0.92 | TSHR (0.70) | TSHRCYP2C9TDP1CYP1A2SMN1; SMN2 | |
| SCHEMBL17124806 | 0.91 | TSHR (0.57) | TSHRCYP2C9TDP1CYP1A2SMN1; SMN2 | |
| SCHEMBL13475556 | 0.90 | TSHR (0.59) | TSHRCYP2C9TDP1CYP1A2SMN1; SMN2 | |
| SCHEMBL5929495 | 0.86 | TSHR (0.67) | TSHRCYP2C9TDP1CYP1A2SMN1; SMN2 | |
| SCHEMBL10111041 | 0.85 | TSHR (0.54) | TSHRCYP2C9TDP1CYP1A2SMN1; SMN2 | |
| SCHEMBL18644135 | 0.85 | TSHR (0.54) | TSHRCYP2C9TDP1CYP1A2SMN1; SMN2 | |
| SCHEMBL20006078 | 0.83 | TSHR (0.60) | TSHRCYP2C9TDP1CYP1A2SMN1; SMN2 | |
| SCHEMBL3373256 | 0.83 | L3MBTL1 (0.67) | CYP2C9TDP1CYP1A2SMN1; SMN2L3MBTL1 | |
| SCHEMBL13068898 | 0.83 | ACHE (0.61) | CYP2C9TDP1CYP1A2SMN1; SMN2L3MBTL1 | |
| SCHEMBL10241943 | 0.82 | TSHR (0.64) | TSHRCYP2C9TDP1CYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096587-B2 | Triazole derivatives as Wnt signaling pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2015-08-04 | — | — | US | disclosed |
| US-8883827-B2 | Azole derivatives as WTN pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2014-11-11 | — | — | US | disclosed |
| US-20140031374-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO University Hospital, HF (NO) | 2014-01-30 | — | — | US | disclosed |
| US-20120208828-A1 | Azole Derivatives as WTN Pathway Inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2012-08-16 | — | — | US | disclosed |
| WO-2012076898-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2012-06-14 | — | — | WO | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| WO-2010139966-A1 | AZOLE DERIVATIVES AS WTN PATHWAY INHIBITORS | OSLO UNIVERSITY HOSPITAL HF (NO) | 2010-12-09 | — | — | WO | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208828-A1 | Azole Derivatives as WTN Pathway Inhibitors | WNT1, AXIN2, WNT3 | TSHR 4638/4885CYP2C9 1123/4885TDP1 4515/4885 |
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | TSHR 1095/4885CYP2C9 211/4885TDP1 2580/4885 |
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | TSHR 3249/4885CYP2C9 280/4885TDP1 2783/4885 |
| US-20140031374-A1 | TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS | CTNNB1, WNT1, CTNNA1 | TSHR 3577/4885CYP2C9 2815/4885TDP1 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.